TALPHERA, INC.
TLPHNext catalyst
NDA Filing - Niyad
Get an email about TLPH's next catalysts
Track TALPHERA (TLPH) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (regulatory event).See the timeline
2 upcoming, 1 past
Regulatory Decision - Niyad
Talphera outlined a plan to seek FDA agreement to end enrollment in the NEPHRO trial by Dec. 31, 2026. The company also raised its peak U.S. sales view for Niyad to over $200M.
SourceNDA Filing - Niyad
Talphera announced plans to file Niyad for PMA (Premarket Approval) in 2026 with anticipated approval in 2027, while NEPHRO trial enrollment has surpassed 50%.
Market Overview
Stock performance and key metrics
morphine IV PCA
Post-Operative Pain
Zalviso™
Moderate-to-severe Acute Pain
Sufentanil
Post-Operative Pain
sufentanil sublingual
Moderate-to-severe Acute Pain
Sufentanil NanoTab PCA System
Pain, Postoperative
Oral sufentanil
Major Upper or Lower Abdominal Surgery
Sufentanil NanoTab
Post Operative Pain
Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)
Sedation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
morphine IV PCA | Phase 3 | Post-Operative Pain | - | - |
Zalviso™ | Phase 3 | Moderate-to-severe Acute Pain | - | - |
Sufentanil | Phase 3 | Post-Operative Pain | - | - |
sufentanil sublingual | Phase 3 | Moderate-to-severe Acute Pain | - | - |
Sufentanil NanoTab PCA System | Phase 3 | Pain, Postoperative | - | - |
Oral sufentanil | Phase 2 | Major Upper or Lower Abdominal Surgery | - | - |
Sufentanil NanoTab | Phase 2 | Post Operative Pain | - | - |
Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03) | Phase 2 | Sedation | - | - |
Continuous renal replacement therapy
1 drug in this indication
Regional anticoagulant for continuous renal replacement therapy (CRRT)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in TALPHERA, INC.'s drug pipeline?→
CatalystAlert tracks 8 drug candidates in TALPHERA, INC.'s (TLPH) pipeline across Phase 3, Phase 2. Its lead program is morphine IV PCA (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TALPHERA, INC.'s next FDA catalyst?→
TALPHERA, INC.'s (TLPH) next tracked catalyst is an NDA filing expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TLPH biotech catalysts?→
Add TLPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TALPHERA, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
